Literature DB >> 21207786

Management of acute ischemic stroke: time is brain.

Marilyn M Rymner1, Naveed Akhtar, Coleman Martin, Debbie Summers.   

Abstract

Treatment of acute ischemic stroke is time dependent and technically challenging. Sixty-four percent of hospitals in the U.S. have never given intravenous (IV) tissue plasminogen activator (tPA) for stroke and 40% of the U.S. population lives in a county without a hospital that routinely treats eligible stroke victims with IV tPA. This, the second in a Missouri Medicine series on stroke, summarizes the available acute treatment options and the evolving role of neuro-imaging in directing therapeutic decisions.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21207786      PMCID： PMC6188407     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  23 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

Authors:  G W Albers; V E Bates; W M Clark; R Bell; P Verro; S A Hamilton
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

3.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.

Authors:  G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

4.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

5.  Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke.

Authors:  Eric E Smith; Abdul R Abdullah; Iva Petkovska; Eric Rosenthal; Walter J Koroshetz; Lee H Schwamm
Journal:  Stroke       Date:  2005-10-06       Impact factor: 7.914

6.  Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Authors:  Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks
Journal:  Stroke       Date:  2007-04-12       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

9.  Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke.

Authors:  Jeffrey L Saver
Journal:  Arch Neurol       Date:  2004-07

10.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321
View more
  2 in total

Review 1.  Circulating Biomarkers in Long-Term Stroke Prognosis: A Scoping Review Focusing on the South African Setting.

Authors:  Juan Jansen van Vuuren; Somasundram Pillay; Ansuya Naidoo
Journal:  Cureus       Date:  2022-04-09

2.  Unraveling the ischemic brain transcriptome in a permanent middle cerebral artery occlusion mouse model by DNA microarray analysis.

Authors:  Motohide Hori; Tomoya Nakamachi; Randeep Rakwal; Junko Shibato; Keisuke Nakamura; Yoshihiro Wada; Daisuke Tsuchikawa; Akira Yoshikawa; Keiji Tamaki; Seiji Shioda
Journal:  Dis Model Mech       Date:  2011-10-20       Impact factor: 5.758
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.